MARKET

MDGL

MDGL

Madrigal Pharmac
NASDAQ
294.64
-4.93
-1.65%
Pre Market: 292.10 -2.54 -0.86% 05:16 05/12 EDT
OPEN
300.11
PREV CLOSE
299.57
HIGH
307.49
LOW
291.16
VOLUME
250
TURNOVER
0
52 WEEK HIGH
377.46
52 WEEK LOW
200.08
MARKET CAP
6.54B
P/E (TTM)
-16.3295
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MDGL last week (0505-0509)?
Weekly Report · 9m ago
Reported Saturday, Madrigal's Rezdiffra Shows Significant Two-Year Improvements In Liver Stiffness And Portal Hypertension Risk In MASH Cirrhosis Patients
Benzinga · 2h ago
Madrigal announces two-year results from Phase 3 MAESTRO-NAFLD-1 trial
TipRanks · 16h ago
Short Report: Bears sell into sharp rally in Hims & Hers
TipRanks · 21h ago
Madrigal Pharmaceuticals Reports Positive Two-Year Results for Rezdiffra in Phase 3 MAESTRO-NAFLD-1 Trial for MASH Cirrhosis
NASDAQ · 1d ago
MADRIGAL PHARMACEUTICALS: 65% OF PATIENTS WITH CLINICALLY SIGNIFICANT PORTAL HYPERTENSION AT BASELINE MOVED INTO LOWER RISK CATEGORIES BY YEAR TWO
Reuters · 1d ago
MADRIGAL PHARMACEUTICALS INC - REZDIFFRA WELL-TOLERATED WITH LOW DISCONTINUATION RATE
Reuters · 1d ago
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
Barchart · 2d ago
More
About MDGL
More
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Recently
Symbol
Price
%Change

Webull offers Madrigal Pharmaceuticals Inc stock information, including NASDAQ: MDGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDGL stock methods without spending real money on the virtual paper trading platform.